About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 127 results
2014
E. Atallah, Bylow, K., Troy, J., and Saber, W., “Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).”, Curr Hematol Malig Rep, vol. 9, no. 1, pp. 57-65, 2014.
2013
J. Mauskopf, Chirila, C., Graham, J., Gersten, I. D., Leather, H., Maziarz, R. T., Baden, L. R., Bolaños-Meade, J., M Y Brown, J., Walsh, T. J., Horowitz, M. H., Kurtzberg, J., Marr, K. A., and Wingard, J. R., “Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.”, Am J Health Syst Pharm, vol. 70, no. 17, pp. 1518-27, 2013.
J. Bolaños-Meade, Wu, J., Logan, B. R., Levine, J. E., Ho, V. T., Alousi, A. M., Weisdorf, D. J., and Luznik, L., “Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.”, Biol Blood Marrow Transplant, vol. 19, no. 3, pp. 481-5, 2013.
J. M. Vose, Carter, S., Burns, L. J., Ayala, E., Press, O. W., Moskowitz, C. H., Stadtmauer, E. A., Mineshi, S., Ambinder, R., Fenske, T., Horowitz, M., Fisher, R., and Tomblyn, M., “Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C”, J Clin Oncol, vol. 31, no. 13, pp. 1662-8, 2013.
B. R. Logan and Zhang, M. - J., “The use of group sequential designs with common competing risks tests.”, Stat Med, vol. 32, no. 6, pp. 899-913, 2013.
2012
J. Levine, Logan, B., Wu, J., Alousi, A. M., Bolaños-Meade, J., Ferrara, J. L. M., Ho, V. T., Weisdorf, D. J., and Paczesny, S., “Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A Blood and Marrow Transplant Clinical Trials Network study.”, 2012.
C. A. Keever-Taylor, Devine, S. M., Soiffer, R. J., Mendizabal, A., Carter, S., Pasquini, M. C., Hari, P. N., Stein, A., Lazarus, H. M., Linker, C., Goldstein, S. C., Stadtmauer, E. A., and O'Reilly, R. J., “Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.”, Biol Blood Marrow Transplant, vol. 18, no. 5, pp. 690-7, 2012.
M. C. Pasquini, Devine, S., Mendizabal, A., Baden, L. R., Wingard, J. R., Lazarus, H. M., Appelbaum, F. R., Keever-Taylor, C. A., Horowitz, M. M., Carter, S., O'Reilly, R. J., and Soiffer, R. J., “Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl”, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.
E. M. Denzen, Santibáñez, M. E. Burton, Moore, H., Foley, A., Gersten, I. D., Gurgol, C., Majhail, N. S., Spellecy, R., Horowitz, M. M., and Murphy, E. A., “Easy-to-read informed consent forms for hematopoietic cell transplantation clinical trials.”, Biol Blood Marrow Transplant, vol. 18, no. 2, pp. 183-9, 2012.
J. Tolar, H Deeg, J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., Adams, R. H., Ewell, M., Leifer, E. S., Gersten, I. D., Carter, S. L., Horowitz, M. M., Nakamura, R., Pulsipher, M. A., DiFronzo, N. L., Confer, D. L., Eapen, M., and Anderlini, P., “Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.”, Biol Blood Marrow Transplant, vol. 18, no. 7, pp. 1007-11, 2012.
B. Foley, Cooley, S., Verneris, M. R., Curtsinger, J., Luo, X., Waller, E. K., Anasetti, C., Weisdorf, D., and Miller, J. S., “Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.”, J Immunol, vol. 189, no. 10, pp. 5082-8, 2012.
P. L. McCarthy, Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. Scott, van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., and Linker, C., “Lenalidomide after stem-cell transplantation for multiple myeloma.”, N Engl J Med, vol. 366, no. 19, pp. 1770-81, 2012.
C. Anasetti, Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., Cutler, C. S., Westervelt, P., Woolfrey, A., Couban, S., Ehninger, G., Johnston, L., Maziarz, R. T., Pulsipher, M. A., Porter, D. L., Mineishi, S., McCarty, J. M., Khan, S. P., Anderlini, P., Bensinger, W. I., Leitman, S. F., Rowley, S. D., Bredeson, C., Carter, S. L., Horowitz, M. M., and Confer, D. L., “Peripheral-blood stem cells versus bone marrow from unrelated donors.”, N Engl J Med, vol. 367, no. 16, pp. 1487-96, 2012.
N. R. Kamani, Walters, M. C., Carter, S., Aquino, V., Brochstein, J. A., Chaudhury, S., Eapen, M., Freed, B. M., Grimley, M., Levine, J. E., Logan, B., Moore, T., Panepinto, J., Parikh, S., Pulsipher, M. A., Sande, J., Schultz, K. R., Spellman, S., and Shenoy, S., “Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 18, no. 8, pp. 1265-72, 2012.
2011
C. G. Brunstein, Fuchs, E. J., Carter, S. L., Karanes, C., Costa, L. J., Wu, J., Devine, S. M., Wingard, J. R., Aljitawi, O. S., Cutler, C. S., Jagasia, M. H., Ballen, K. K., Eapen, M., and O'Donnell, P. V., “Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.”, Blood, vol. 118, no. 2, pp. 282-8, 2011.
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., “Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.”, Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
M. R. Tomblyn, Ewell, M., Bredeson, C., Kahl, B. S., Goodman, S. A., Horowitz, M. M., Vose, J. M., Negrin, R. S., and Laport, G. G., “Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.”, Biol Blood Marrow Transplant, vol. 17, no. 7, pp. 1051-7, 2011.
D. B. Kohn, Dotti, G., Brentjens, R., Savoldo, B., Jensen, M., Cooper, L. Jn, June, C. H., Rosenberg, S., Sadelain, M., and Heslop, H. E., “CARs on track in the clinic.”, Mol Ther, vol. 19, no. 3, pp. 432-8, 2011.
E. M. Horwitz, Horowitz, M. M., DiFronzo, N. L., Kohn, D. B., and Heslop, H. E., “Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 17, no. 2, pp. 192-6, 2011.
S. M. Devine, Carter, S., Soiffer, R. J., Pasquini, M. C., Hari, P. N., Stein, A., Lazarus, H. M., Linker, C., Stadtmauer, E. A., Alyea, E. P., Keever-Taylor, C. A., and O'Reilly, R. J., “Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot”, Biol Blood Marrow Transplant, vol. 17, no. 9, pp. 1343-51, 2011.
M. A. Pulsipher, Young, N. S., Tolar, J., Risitano, A. M., H Deeg, J., Anderlini, P., Calado, R., Kojima, S., Eapen, M., Harris, R., Scheinberg, P., Savage, S., Maciejewski, J. P., Tiu, R. V., DiFronzo, N., Horowitz, M. M., and Antin, J. H., “Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network,”, Biol Blood Marrow Transplant, vol. 17, no. 3, pp. 291-9, 2011.
2010
J. E. Levine, Logan, B., Wu, J., Alousi, A. M., Ho, V., Bolaños-Meade, J., and Weisdorf, D., “Graft-versus-host disease treatment: predictors of survival.”, Biol Blood Marrow Transplant, vol. 16, no. 12, pp. 1693-9, 2010.
P. A. Jacobson, Huang, J., Wu, J., Kim, M., Logan, B., Alousi, A., Grimley, M., Bolaños-Meade, J., Ho, V., Levine, J. E., and Weisdorf, D., “Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 16, no. 3, pp. 421-9, 2010.
J. R. Wingard, Carter, S. L., Walsh, T. J., Kurtzberg, J., Small, T. N., Baden, L. R., Gersten, I. D., Mendizabal, A. M., Leather, H. L., Confer, D. L., Maziarz, R. T., Stadtmauer, E. A., Bolaños-Meade, J., Brown, J., DiPersio, J. F., Boeckh, M., and Marr, K. A., “Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.”, Blood, vol. 116, no. 24, pp. 5111-8, 2010.
2009
A. M. Alousi, Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., Wingard, J. R., Horowitz, M. M., and Levine, J. E., “Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.”, Blood, vol. 114, no. 3, pp. 511-7, 2009.